Fortrea (NASDAQ:FTRE – Get Free Report) and Nutra Pharma (OTCMKTS:NPHC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Volatility & Risk
Fortrea has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.
Valuation & Earnings
This table compares Fortrea and Nutra Pharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fortrea | $2.72 billion | 0.61 | -$986.20 million | ($4.91) | -3.59 |
| Nutra Pharma | $380,000.00 | 3.77 | -$2.05 million | N/A | N/A |
Nutra Pharma has lower revenue, but higher earnings than Fortrea.
Profitability
This table compares Fortrea and Nutra Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortrea | -16.50% | 9.51% | 1.96% |
| Nutra Pharma | -364.90% | N/A | -159.08% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Fortrea and Nutra Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortrea | 1 | 5 | 5 | 0 | 2.36 |
| Nutra Pharma | 0 | 0 | 0 | 0 | 0.00 |
Fortrea currently has a consensus price target of $17.45, suggesting a potential downside of 1.13%. Given Fortrea’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Fortrea is more favorable than Nutra Pharma.
Summary
Fortrea beats Nutra Pharma on 8 of the 10 factors compared between the two stocks.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
About Nutra Pharma
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
